search
Back to results

Graz Study on the Risk of Atrial Fibrillation (GRAF)

Primary Purpose

Atrial Fibrillation, Hypertension, Diabetes

Status
Unknown status
Phase
Phase 4
Locations
Austria
Study Type
Interventional
Intervention
Medtronic Reveal XT implantable loop recorder
Sponsored by
Medical University of Graz
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Atrial Fibrillation focused on measuring atrial fibrillation, biomarkers, stroke prevention, implantable loop recorder

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • CHA2DS2-VASc risk score >= 4*
  • 18 years or older

Exclusion Criteria:

  • known history of atrial fibrillation
  • implanted rhythm device
  • pre-existing indication for oral anticoagulation

(*)CHA2DS2-VASc: C - chronic heart failure (1 point); H - hypertension (1 point); A - age >= 75 years (2 points); D - diabetes (1 point); S - stroke (2 points); V - vascular disease (1 point); A - age >=65 and < 75 years (1 point); Sc - sex category (female) (1 point) ;

Sites / Locations

  • LKH/Uniklinikum - Klinische Abteilung für Kardiologie

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

loop recorder

regular follow-up

Arm Description

patients will be implanted with a subcutaneous loop recorder and have regular follow-ups

patients will receive regular follow-ups with standard ECG

Outcomes

Primary Outcome Measures

Time to first diagnosis of atrial fibrillation

Secondary Outcome Measures

Time to change in therapy based on the diagnosis of atrial fibrillation
Hospitalizations
Change in NTproBNP serum level associated with occurrence of atrial fibrillation
Death
Stroke

Full Information

First Posted
October 23, 2011
Last Updated
December 20, 2015
Sponsor
Medical University of Graz
Collaborators
Medtronic
search

1. Study Identification

Unique Protocol Identification Number
NCT01461434
Brief Title
Graz Study on the Risk of Atrial Fibrillation
Acronym
GRAF
Official Title
Randomized Controlled Trial to Evaluate Implanted Event Recorders for the First Diagnosis of Atrial Fibrillation in High-risk Patients
Study Type
Interventional

2. Study Status

Record Verification Date
December 2015
Overall Recruitment Status
Unknown status
Study Start Date
November 2011 (undefined)
Primary Completion Date
May 2015 (Actual)
Study Completion Date
January 2016 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Medical University of Graz
Collaborators
Medtronic

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Atrial fibrillation (AF) is the most common clinical arrhythmia. AF is associated with increased risk for stroke due to blood clots formed in the fibrillating atria. Some patient characteristics increase the likelyhood of AF and at the same time the risk of stroke when AF has developed. To reduce the risk of stroke, anticoagulation therapy is recommended in patients with AF and risk factors (such as high blood pressure, diabetes, vessel disease). However, occasional (paroxysmal) AF may occur without symptoms and remain undetected, leaving patients at risk. Aim of the prospective randomized study is to compare two management strategies for patients at increased risk for AF but without a known history of AF. Patients are seen regularly (monthly, then quarterly) for follow-up (incl. ECG recording and blood sample). One group of patients additionally receives a subcutaneous implantation of a loop recorder for continuous rhythm monitoring, while the control group remains on standard follow-up. Observation period is one year (optional extension for 3 years). The time to first diagnosis of AF is compared between groups, blood samples are analyzed for potential biomarkers of AF.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation, Hypertension, Diabetes, Chronic Heart Failure, Vascular Disease
Keywords
atrial fibrillation, biomarkers, stroke prevention, implantable loop recorder

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
82 (Actual)

8. Arms, Groups, and Interventions

Arm Title
loop recorder
Arm Type
Experimental
Arm Description
patients will be implanted with a subcutaneous loop recorder and have regular follow-ups
Arm Title
regular follow-up
Arm Type
No Intervention
Arm Description
patients will receive regular follow-ups with standard ECG
Intervention Type
Device
Intervention Name(s)
Medtronic Reveal XT implantable loop recorder
Intervention Description
subcutaneous implantation
Primary Outcome Measure Information:
Title
Time to first diagnosis of atrial fibrillation
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Time to change in therapy based on the diagnosis of atrial fibrillation
Time Frame
Baseline (0 months), 1,2,3,4,5,6,9 and 12 months
Title
Hospitalizations
Time Frame
12 months
Title
Change in NTproBNP serum level associated with occurrence of atrial fibrillation
Time Frame
Baseline (0 months), 1,2,3,4,5,6,9 and 12 months
Title
Death
Time Frame
12 months
Title
Stroke
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: CHA2DS2-VASc risk score >= 4* 18 years or older Exclusion Criteria: known history of atrial fibrillation implanted rhythm device pre-existing indication for oral anticoagulation (*)CHA2DS2-VASc: C - chronic heart failure (1 point); H - hypertension (1 point); A - age >= 75 years (2 points); D - diabetes (1 point); S - stroke (2 points); V - vascular disease (1 point); A - age >=65 and < 75 years (1 point); Sc - sex category (female) (1 point) ;
Facility Information:
Facility Name
LKH/Uniklinikum - Klinische Abteilung für Kardiologie
City
Graz
ZIP/Postal Code
8036
Country
Austria

12. IPD Sharing Statement

Learn more about this trial

Graz Study on the Risk of Atrial Fibrillation

We'll reach out to this number within 24 hrs